Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYML-122 plus cytarabine in relapsed or refractory FLT3-mutated AML
ChiCTR2100051198Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CHMFL-FLT3-122 and cytarabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective response rate. Started Oct 2021; status: recruiting.
02
Drugs
CHMFL-FLT3-122cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100051198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051198.